ASSA13-11-9 Rosuvastatin Prevents Contrast-Induced Nephropathy in Diabetic Nephropathy Rats

Abstract

<h3>Objective</h3> The aim of the present study was to assess the effects of rosuvastatin on contrast-induced nephropathy (CIN) in diabetic nephropathy rats. <h3>Methods</h3> Male SD rats, using a single intraperitoneal injection of streptozotocin (STZ) to create a diabetic nephropathy model. The model rats were randomly grouped into diabetic nephropathy group, contrast group and the rosuvastatin+ contrast group, 10 ineach group. Intravenous injection of iopromide (3500 u/kg) given 72 hours later, the line serum creatinine testing, to determine the CIN formation. The serum total cholesterol, triglycerides, creatinine, nitric oxide, interleukin-6, and tumour necrosis factor alpha levels were analysed. Urine samples were taken to measure the albumin/urinary creatinine ratio. Kidneys were sectioned and stained with hematoxylin/eosin and Masson’s trichrome. Immunohistochemical analysis of the renal tissue was performed to detect macrophage infiltration of the glomeruli. <h3>Results</h3> The contrast group had a significantly reduced nitric oxide level and an increased interleukin-6 and tumour necrosis factor alpha level, albumin/urinary creatinine ratio and number of macrophages in the renal glomeruli. Rosuvastatin increased the nitric oxide level and reduced the interleukin-6 and tumour necrosis factor alpha levels, glomerular macrophage number and albumin/urinary creatinine ratio in the contrast +rosuvastatin group. <h3>Conclusions</h3> Rosuvastatin treatment reduced glomerular damage due to improvement in the inflammatory pattern independent of serum lipid level. These effects may lead to improvements in the treatment of CIN.